In Person

BIO International Convention

June 4 – 7, 2018
Event details
June 4 – 7, 2018
12:00 am
415 Summer Street, Boston, MA

Event summary

The BIO International Convention is the largest global event for the biotechnology industry, attracting 16,000+ biotechnology and pharma leaders while covering a wide range of life science and application areas.

Featured Cooley Panels:

Friday, June 1 – Sunday, June 3, 2018: Room 210B, Level 2
Advanced Business Development Course 
The Advanced Business Development Course is designed for executives and business development professionals interested in bringing their skills in valuation, deal structuring, due diligence, negotiation and contracts to the next level. During this intense, three-day workshop attendees will receive hands-on, advanced training from veteran business development professionals and legal advisers using real world case studies. In addition, attendees will be split into teams to conduct a mock negotiation over rights for a clinical stage compound.

Debbie Allen – Senior Vice President Business Development, arGEN-X
Joseph Dillon – President, Dillon Capital Strategies
Luke Kempton – Partner, Gowling WLG
Kenneth Krisko – Partner, Cooley
Lesley Stolz – Head of JLabs California, Johnson & Johnson Innovation

Monday, June 4, 2018: 1:00 pm – 2:15 pm, Room 252AB, Level 2
Achieving Success with the Build-to-Buy Model
According to a recent report by BioCentury, there have been nearly 40 start-ups engaging in build-to-buy deals since 2013. The build-to-buy model can be helpful to mitigate the inherent risk that comes along with new scientific discoveries and provide a solid exit strategy for early stage companies. By working in conjunction with a venture partner or negotiating a direct deal with pharma, our panel of experienced build-to-buy dealmakers from Cooley, PvP Biologics, Tempest Therapeutics and academia will share how this model has generated success for venture capitalists, founders and stakeholders.

Abi Barrow – Interim Executive Director, Office of Technology Commercialization and Ventures at the University of Massachusetts
Paul Grayson– President & CEO, Bird Rock Bio
Alicia Levey– Vice President of Business Development and Strategy, Tempest Therapeutics
Rama Padmanabhan – Partner, Cooley
Veronique Riethuisen – Vice President GI, Regenerative Medicine, Externalization R&D BD, Takeda
Adam Simpson – President and CEO, PvP Biologics

Tuesday, June 5, 2018: 10:45 am – 11:00 am, Room 210C, Level 2
BIO Digital Health Track Opening Remarks by Wainwright Fishburn, Jr., Partner at Cooley and Chair of the BIO Digital Health Track, 2014 – 2018

Tuesday, June 5, 2018: 11:00 am – 12:00 pm, Room 210C, Level 2
Tech-Enabling the Healthcare Sector: A Fireside Chat with John Sculley, Chairman, RxAdvance
John Sculley, chairman of RxAdvance and former CEO of Apple, believes monumental shifts in healthcare are on the horizon. Healthcare remains one of the last major sectors to be fully tech-enabled. Join us for a fireside chat with John, where he will describe his transition from tech into healthcare tech, where he has spent the better part of the last decade. John will discuss how RxAdvance, an innovative national full-service pharmacy benefit manager, will serve as a disrupter to the ecosystem. The RxAdvance platform represents an opportunity to directly impact healthcare costs through technology innovation, reducing pharmacy costs and avoidable drug-impacted medical costs.

Wainwright Fishburn, Jr. – Partner, Cooley and Chair, BIO Digital Health Track, 2014 – 2018
John Sculley – Chairman, RxAdvance

Tuesday, June 5, 2018: 1:45 pm – 2:45 pm, Room 210C, Level 2
A Look to the Future: Investors Corner – 2018 & Beyond
Funding for digital health has continued to reach new highs in 2018 and more than $17B has been invested over the last five years. The sector is maturing, and early entrants are now seeking validation and pursuing viable regulatory pathways. Our panel of active venture capital investors will share their perspectives on market trends and predictions for the breakout companies and sectors in 2018 and beyond.

A.G. Breitenstein – Partner, Optum Ventures
Wainwright Fishburn, Jr. – Partner, Cooley and Chair, BIO Digital Health Track, 2014 – 2018
Michael Greeley – Co-Founder and Partner, Flare Capital
Stephen Kraus – Partner, Bessemer Ventures

Tuesday, June 5, 2018: 3:00 pm – 4:00 pm, Room 208, Level 2
Hatch-Waxman ANDA Cases and IPRs
The panel will discuss how Hatch-Waxman (HW) ANDA cases (patent cases between branded and generic pharma) are being impacted by the new Inter Partes Review (IPR) procedures in the Patent Office, wherein parties can ask the Patent Office to find a granted patent invalid. The IPR procedures allow generics and others to invalidate a pharmaceutical patent under a much lower standard than exists in federal court where HW cases play out. The presence of a parallel IPR procedure in the Patent Office during a HW federal court lawsuit raises many questions about competing power and expertise between the Courts and the Patent Office, the propriety of the Patent Office's lower standard and whether such dual track procedures advance the goals of HW and the patent system – to promote innovation and also to expedite generic competition.

Moderator: Jason Lief – Special Counsel, Cooley
James Harrington – Senior Vice President and Chief Intellectual Property Counsel, Shire Pharmaceuticals
Judge Faith Hochberg – Judge, Hochberg ADR

Tuesday, June 5, 2018: 3:00 pm – 4:00 pm, Room 210C, Level 2
Digital Medicines: Lessons Learned and Challenges Ahead
Digital medicine have the potential to revolutionize healthcare. Similarly, consumer genomics will change the paradigm for healthcare choices and treatment options for patients. This session will unpack the challenges and successes faced along the way for both early entrants and newcomers to the sector.

Moderator: Geoff Starr – Partner, Cooley
Don Jones – Chief Digital Officer, Scripps Translational Science Institute
Adam Kaufman – President & CEO, Canary Health
Tim Peters-Strickland – Senior Director and Global Clinical Development, Otsuka Pharmaceutical Co. Limited

Tuesday, June 5, 2018: 4:15 pm – 5:15 pm, Room 210C, Level 2
Breakthrough Business Models
As the digital health ecosystem evolves, new business models are emerging to address the biggest opportunities – and biggest threats – in the market. What types of business models are emerging to address these opportunities? As the genomic marketplace matures, will new platforms such as blockchain solve the challenge of large genomic data sets? Disrupters are paving new opportunities for entrants, with the potential for new business models to displace how we currently consume and manage our healthcare information.

Speaker & Moderator: John Mattison – Chief Medical Information Officer, Kaiser Permanente
Dawn Barry – Co-Founder & President, Luna DNA
Sumit Jamuar – Chairman & CEO, Global Gene Corp
Tony Wang – COO, Color Genomics

Company presentations sponsored by Cooley
Cooley is proud to sponsor the various company presentations happening throughout the BIO 2018 Conference. These presentations provide companies the opportunity to pitch their story, pipelines and objectives to a global audience representing 70+ countries. 

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.